|
Diabetes Mellitus, Non-Insulin-Dependent
|
0.060 |
Biomarker
|
disease |
BEFREE |
PRACTICAL APPLICATIONS: Mfn2 and Drp1, as the main regulators of the mitochondrial fusion and fission, play an important role in maintaining mitochondrial dynamics and type 2 diabetes.
|
31849103 |
2020 |
|
Optic Atrophy 1
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, the mRNA and protein expression of dynamin-related protein 1 (Drp1), mitochondrial fission factor (Mff), mitofusin 1 and 2 (Mfn1 and Mfn2), optic atrophy 1 (Opa1) indicated imbalance between mitochondrial inner and outer membrane and results in mitochondrial dysfunction in broilers BF.
|
31841897 |
2020 |
|
Fibrosis, Liver
|
0.010 |
Biomarker
|
disease |
BEFREE |
Taken together, our findings indicate that MFN2 is critical in regulating apoptosis and liver fibrosis in HSCs, which might be a useful therapeutic target to treat liver fibrosis.
|
31802713 |
2020 |
|
HIV Infections
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Here, we show that upon HIV infection, macrophages increase the expression of BCL2, BCLXL, TREM1, mitofusin 1 (MFN1), and MFN2 and the translocation of BCL2L11 (BIM) to the mitochondria and decrease the expression of BCL2-associated agonist of cell death (BAD) and BAX while maintaining a 95% survival rate over 28 days.
|
31719184 |
2019 |
|
Optic Atrophy 1
|
0.100 |
Biomarker
|
disease |
BEFREE |
The neurotoxin 6-hydroxydopamine (6-OHDA) treated with SH-SY5Y cells decreased OPA1 and mitofusin 2 fusion proteins, but increased fission 1 and dynamin related protein 1 (DRP1) fission proteins.
|
31705926 |
2020 |
|
Neurodegenerative Disorders
|
0.100 |
GeneticVariation
|
group |
BEFREE |
Mutations in MFN2 cause the neurodegenerative disease Charcot-Marie-Tooth type 2A (CMT2A).
|
31664033 |
2019 |
|
Parkinson Disease
|
0.050 |
AlteredExpression
|
disease |
BEFREE |
In the current study, we utilized a 6-hydroxydopamine (6-OHDA) lesioned rat model of PD to explore the protective efficacy of polyphenolic phytochemical ferulic acid (FA) against mitochondrial dysfunction and explored its effect on gene and protein expression of mitochondrial dynamics regulators dynamin-related protein 1 (Drp1)/mitofusin 2 (Mfn2) in lesioned animals.
|
31657074 |
2020 |
|
Coronary Arteriosclerosis
|
0.010 |
Biomarker
|
disease |
BEFREE |
PTEN inhibition attenuates endothelial cell apoptosis in coronary heart disease via modulating the AMPK-CREB-Mfn2-mitophagy signaling pathway.
|
31654396 |
2020 |
|
Coronary heart disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
PTEN inhibition attenuates endothelial cell apoptosis in coronary heart disease via modulating the AMPK-CREB-Mfn2-mitophagy signaling pathway.
|
31654396 |
2020 |
|
Coronary Artery Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
PTEN inhibition attenuates endothelial cell apoptosis in coronary heart disease via modulating the AMPK-CREB-Mfn2-mitophagy signaling pathway.
|
31654396 |
2020 |
|
Distal amyotrophy
|
0.110 |
GeneticVariation
|
disease |
BEFREE |
Autosomal-dominant inheritance of a R94Q mutation in MFN2 causes the axonal subtype 2A2A which is characterized by early onset and progressive atrophy of distal muscles caused by motoneuronal degeneration.
|
31640251 |
2019 |
|
Renal fibrosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
In addition, mitophagy in macrophages involves PINK1-mediated phosphorylation of downstream MFN2, MFN2-facilitated recruitment of Parkin to damaged mitochondria, and macrophage-specific deletion of Mfn2 aggravates kidney fibrosis.
|
31639106 |
2019 |
|
Mitochondrial Diseases
|
0.030 |
GeneticVariation
|
group |
BEFREE |
Mutations within Mfn1 or Mfn2 impair mitochondrial fusion and lead to some severe mitochondrial dysfunctions and mitochondrial diseases (MDs).
|
31609634 |
2019 |
|
Acute-On-Chronic Liver Failure
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Mfn2 improved the expressions of LC3-II, Atg5 and Bcl-2 and down-regulated the expression of P62 and Bax in ACLF.
|
31557386 |
2019 |
|
Optic Atrophy 1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Mitochondrial fusion is primarily controlled by three GTPases, mitofusin 1 (Mfn1), Mfn2, and optic atrophy 1 (Opa1), while mitochondrial fission is primarily regulated by GTPase dynamin-related protein 1 (Drp1).
|
31551926 |
2019 |
|
Malignant neoplasm of breast
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
PTEN and MFN2 protein expressions were negative correlated with Vmax and positively correlated with RI in breast cancer patients.
|
31535669 |
2019 |
|
Breast Carcinoma
|
0.060 |
AlteredExpression
|
disease |
BEFREE |
PTEN and MFN2 protein expressions were negative correlated with Vmax and positively correlated with RI in breast cancer patients.
|
31535669 |
2019 |
|
Optic Atrophy 1
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, both HIIT and MICT interventions down-regulated dynamin-related protein 1 (DRP1) and fission 1 (FIS1), whereas mitofusin 1 (MFN1), mitofusin 2 (MFN2) and optic atrophy 1 (OPA1) were up-regulated.
|
31445975 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
MFN2 expression was associated with tumor stage, tumor grade and lymph node status.
|
31402945 |
2019 |
|
Tumor Cell Invasion
|
0.060 |
Biomarker
|
phenotype |
BEFREE |
MFN2 knockdown by small interfering RNA promoted cancer cell proliferation, migration and invasion <i>in vitro</i>, and enhanced tumor progression <i>in vivo</i>.
|
31402945 |
2019 |
|
Tumor Progression
|
0.030 |
Biomarker
|
phenotype |
BEFREE |
MFN2 knockdown by small interfering RNA promoted cancer cell proliferation, migration and invasion <i>in vitro</i>, and enhanced tumor progression <i>in vivo</i>.
|
31402945 |
2019 |
|
Carcinoma of bladder
|
0.020 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry was used to investigate MFN2 expression in 117 bladder cancer specimens.
|
31402945 |
2019 |
|
Malignant neoplasm of urinary bladder
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry was used to investigate MFN2 expression in 117 bladder cancer specimens.
|
31402945 |
2019 |
|
Bladder Neoplasm
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemistry was used to investigate MFN2 expression in 117 bladder cancer specimens.
|
31402945 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Then, the in vivo experiment also confirmed that Mfn2 could inhibit the tumor growth, and depress the Cyclin D1, Ras, Myc, NF-κB p65, Erk1/2 and mTOR protein expression.
|
31384172 |
2019 |